Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, single arm phase II study.

Takeshi Kato, Hidetoshi Eguchi, Mamoru Uemura et al.|Journal of Clinical Oncology|2020

Cited by 0